According to a study published in Blood Advances, patients with multiple myeloma who received idecabtagene vicleucel, also known as "ide-cel," a chimeric antigen receptor (CAR) T-cell treatment, exhibited no change in overall survival outcomes regardless of race or ethnicity.
According to a new study living in a more walkable neighbourhood reduces the risk of obesity-related cancers in women, specifically postmenopausal breast cancer, but also ovarian cancer, endometrial cancer, and multiple myeloma.
People with multiple myeloma, a blood malignancy of plasma cells in the bone marrow, have a poorer overall survival rate when compared to individuals without diabetes. This difference in survival due to diabetes was found in white patients in a subgroup analysis but not in black patients, ac
When compared to people without diabetes, those with multiple myeloma, a blood malignancy of plasma cells in the bone marrow, have a worse overall survival rate. According to a study published today in Blood Advances, this difference in survival related to diabetes was detected in white pati
In a ground-breaking development in the fight against myeloma, Israeli researchers developed a targeted procedure to effectively destroy cancer within the bone marrow.
According to a study by the University of Pennsylvania, multiple myeloma, a type of bone marrow cancer, could be potentially treated by a first-of-its-kind drug.
The treatment, which is referred to as a "bispecific antibody," binds to both T cells and multiple myeloma cells and instructs the T cells, which are white blood cells that can be used to fight off diseases
Vellore (Tamil Nadu) [India], December 9 (ANI/NewsVoir): BD Life Sciences-Biosciences, a segment of BD (Becton, Dickinson, and Company) in collaboration with The Cytometry Society of India, Christian Medical College - Vellore organized a 2-day workshop for laboratory personnel on technologic
The study discovered new treatments that can assist patients with multiple myeloma, a blood cancer, who have tried the immunotherapy CAR-T but have experienced relapses.
Researchers have identified therapies that can help patients with multiple myeloma blood cancer who try an immunotherapy known as CAR-T only to find their cancer returning afterwards.